138 related articles for article (PubMed ID: 34165783)
21. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
[TBL] [Abstract][Full Text] [Related]
22. Cyclin D1 as the putative bcl-1 oncogene.
Harris AW; Bodrug SE; Warner BJ; Bath ML; Lindeman GJ; Adams JM
Curr Top Microbiol Immunol; 1995; 194():347-53. PubMed ID: 7895508
[No Abstract] [Full Text] [Related]
23. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
Fonseca R; Blood EA; Oken MM; Kyle RA; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Hoyer JD; Harrington D; Kay NE; Van Ness B; Greipp PR
Blood; 2002 May; 99(10):3735-41. PubMed ID: 11986230
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma.
Fonseca R; Hoyer JD; Aguayo P; Jalal SM; Ahmann GJ; Rajkumar SV; Witzig TE; Lacy MQ; Dispenzieri A; Gertz MA; Kyle RA; Greipp PR
Leuk Lymphoma; 1999 Nov; 35(5-6):599-605. PubMed ID: 10609798
[TBL] [Abstract][Full Text] [Related]
25. Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax.
Soleimani A; Koka M; Singh ZN; Kesari V; Badros A
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e556-e559. PubMed ID: 32653454
[No Abstract] [Full Text] [Related]
26. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
27. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.
Chang H; Sloan S; Li D; Zhuang L; Yi QL; Chen CI; Reece D; Chun K; Keith Stewart A
Br J Haematol; 2004 Apr; 125(1):64-8. PubMed ID: 15015970
[TBL] [Abstract][Full Text] [Related]
28. Analysis of clonal relationship using single-cell polymerase chain reaction in a patient with concomitant mantle cell lymphoma and multiple myeloma.
Yamaguchi M; Ohno T; Miyata E; Toyoda H; Nishii K; Masuya M; Kita K; Shiku H
Int J Hematol; 2001 Apr; 73(3):383-5. PubMed ID: 11345207
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
Wong KY; Chim CS
J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).
Ghilardi G; Stussi G; Mazzucchelli L; Röcken C; Rossi D; Gerber B
Amyloid; 2019 Sep; 26(3):173-174. PubMed ID: 31232114
[No Abstract] [Full Text] [Related]
31. [Detection of deletion of the long arm of chromosome 13 and translocation of immunoglobulin heavy chain gene by interphase fluorescence in situ hybridization in patients with multiple myeloma].
Sun WL; Wu YJ; Li H; Wang X; Zhuang JL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):485-90. PubMed ID: 18795626
[TBL] [Abstract][Full Text] [Related]
32. Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients.
Butler C; Wolff DJ; Kang Y; Stuart RK; Costa LJ
Leuk Lymphoma; 2012 Dec; 53(12):2444-8. PubMed ID: 22574971
[TBL] [Abstract][Full Text] [Related]
33. Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents.
Sato S; Kamata W; Okada S; Tamai Y
Int J Hematol; 2021 Feb; 113(2):207-213. PubMed ID: 32949373
[TBL] [Abstract][Full Text] [Related]
34. Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence.
Cook JR; Hartke M; Pettay J; Tubbs RR
J Mol Diagn; 2006 Sep; 8(4):459-65. PubMed ID: 16931586
[TBL] [Abstract][Full Text] [Related]
35. Various patterns of IgH deletion identified by FISH using combined IgH and IgH/CCND1 probes in multiple myeloma and chronic lymphocytic leukemia.
Hwang Y; Lee JY; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2011 Jun; 33(3):299-304. PubMed ID: 21272268
[TBL] [Abstract][Full Text] [Related]
36. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.
Grzasko N; Hus M; Chocholska S; Pluta A; Hajek R; Dmoszynska A
Leuk Lymphoma; 2012 Dec; 53(12):2500-3. PubMed ID: 22497640
[No Abstract] [Full Text] [Related]
37. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
Jelinek T; Mihalyova J; Kascak M; Duras J; Popkova T; Benkova K; Richterova P; Plonkova H; Zuchnicka J; Broskevicova L; Huvarova L; Cerna L; Growkova K; Simicek M; Havel M; Gumulec J; Navratil M; Koristek Z; Paiva B; Hajek R
Am J Hematol; 2019 Jan; 94(1):E35-E37. PubMed ID: 30370955
[No Abstract] [Full Text] [Related]
38. t(11;14) does not predict long-term survival in myeloma.
Chang H; Qi XY; Stewart AK
Leukemia; 2005 Jun; 19(6):1078-9. PubMed ID: 15815719
[No Abstract] [Full Text] [Related]
39. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
Matulis SM; Gupta VA; Neri P; Bahlis NJ; Maciag P; Leverson JD; Heffner LT; Lonial S; Nooka AK; Kaufman JL; Boise LH
Leukemia; 2019 May; 33(5):1291-1296. PubMed ID: 30679802
[No Abstract] [Full Text] [Related]
40. Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results.
Harrison CJ; Mazzullo H; Cheung KL; Gerrard G; Jalali GR; Mehta A; Osier DG; Orchard KH
Br J Haematol; 2003 Mar; 120(6):944-52. PubMed ID: 12648063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
